Chiusura precedente | 62,40 |
Aperto | 62,30 |
Denaro | 63,18 x 1400 |
Lettera | 63,30 x 800 |
Min-Max giorno | 62,13 - 63,59 |
Intervallo di 52 settimane | 56,56 - 85,97 |
Volume | 9.361.943 |
Media Volume | 9.860.614 |
Capitalizzazione | 79,386B |
Beta (5 anni mensile) | 0,53 |
Rapporto PE (ttm) | 62,89 |
EPS (ttm) | 1,01 |
Prossima data utili | 02 feb 2021 - 08 feb 2021 |
Rendimento e dividendo (forward) | 2,72 (4,29%) |
Data ex dividendo | 14 dic 2020 |
Stima target 1A | 72,46 |
The U.S. drugmaker Gilead Sciences revised its full-year 2020 profit guidance as the second wave of coronavirus infections boosted the demand of Remdesivir, an antiviral agent that scientists initially designed to treat Ebola, also, beneficial for COVID-19 treatment.
Gilead Sciences said that the U.S. Food and Drug Administration has approved the antiviral drug remdesivir for the COVID-19 treatment, sending its shares up about 6% in pre-market on Friday.
Gilead Sciences Inc, an American biopharmaceutical company that researches, develops and commercializes drugs, announced to acquire a pharmaceutical company Immunomedics Inc for $21 billion or $88.00 per share in cash, a move that will help strengthen its drugs portfolio for cancer.